Corporate Banner
Satellite Banner
RNAi
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Crown Bioscience Announces Research Collaboration with the NRCMM

Published: Saturday, May 10, 2014
Last Updated: Saturday, May 10, 2014
Bookmark and Share
New collaboration aims to develop disease-specific experimental models for translational medical research.

Crown Bioscience, Inc. has announced that an agreement has been reached with the National Resource Center for Mutant Mice (NRCMM), in Nanjing, Jiangsu Province, China.

The strategic partnership will focus on developing new experimental cancer models to advance translational medical research and the treatment of cancers.

The immediate focus of the research collaboration will be to build new experimental models for cancer research leveraging the proprietary technologies of both companies.

The collaboration is expected to significantly expand the research capabilities of both organizations in translational oncology and will thus benefit the global research community fighting cancers.

Crown Bioscience is the premier service provider of translational oncology and metabolic diseases platforms providing focused disease models. It has one of the largest and most advanced translational oncology platforms featuring fully annotated collections of proprietary patient derived xenograft (PDX) models (>1000).

NRCMM is a leading research organization specialized in genetically engineered mutant mouse (GEMM), with vast resources, including a large collection of GEMMs, many of which mimic human cancers. Both parties have complimentary expertise and experience in Oncology and GEMMs, and therefore the established joint effort will have great synergy in creating new translational oncology platforms based on GEMMs.

The collaboration will offer significantly expanded new mouse cancer and leukemia models based on GEMM as well as new human xenografts, in addition to the current PDX and CDX platforms (Cell line Derived Xenograft) at Crown and the current GEMMs at NRCMM.

In particular, novel mouse strains with various humanizations could be particularly powerful tools for immune-oncology research and immunotherapy drug evaluations.

After the signing of the agreement, Dr. Jean-Pierre Wery, Crown’s President, commented: “Crown plays a leading role in providing cutting-edge translational platforms and cost effective drug development solutions for almost all top pharmaceutical companies worldwide. Crown is very happy to partner with NRCMM, the leading research institute for genetically engineered animals in China. This partnership will offer world-class translational oncology services, and ultimately benefit cancer patients around the world. This collaboration will further strengthen Crown’s leading position as the oncology translational medicine partner for drug discovery organizations worldwide”.

Dr. Gao, Director of NRCMM, also commented: “As the largest government-funded research institute focusing on genetically engineered mice in China, NRCMM is an important member of the global community of GEMM research. Working together with a world leading translational oncology service provider, such as Crown, the combined expertise of Crown in oncology and our GEMM can certainly offer great GEMM-based oncology platforms to our partners in China and around the world. We are certainly excited about this opportunity.”


Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,400+ scientific posters on ePosters
  • More than 3,700+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Crown Bioscience Announces U.S. Expansion
New service center will allow the expansion of new immunotherapy experimental platforms to advance translational medical research and the treatment of cancers.
Saturday, October 25, 2014
Crown Reveals Strategy for Combined Drug-IR Therapy to Overcome Resistance
Novel strategies for combining drug therapy with irradiation to deliver new hope for overcoming resistance in the clinic.
Saturday, June 21, 2014
Crown Bioscience Receives $26.55M Series D Funding
Investment will fund rapid expansion in translational platform technologies for oncology and metabolic diseases.
Monday, May 12, 2014
SIMM and Crown Bioscience Reach Landmark Agreement
Agreement to develop world-leading mouse clinical center and largest annotated PDX and translational oncology platform.
Friday, November 29, 2013
Crown Bioscience Enter Into a Business Collaboration with Xstrahl Ltd
Development of radiation models of cancer will enable the discovery of more effective oncology therapies.
Tuesday, October 15, 2013
Scientific News
RNAi Screening Trends
Understand current trends and learn which application areas are expected to gain in popularity over the next few years.
New Material Opens Possibilities for Super-Long-Acting Pills
A pH-responsive polymer gel could create swallow able devices, including capsules for ultra-long drug delivery.
New Tool For Investigating RNA Gone Awry
A new technology – called “Sticky-flares” – developed by nanomedicine experts at Northwestern University offers the first real-time method to track and observe the dynamics of RNA distribution as it is transported inside living cells.
Access Denied: Leukemia Thwarted by Cutting Off Link to Environmental Support
A new study reveals a protein’s critical – and previously unknown -- role in the development and progression of acute myeloid leukemia (AML), a fast-growing and extremely difficult-to-treat blood cancer.
New Weapon in the Fight Against Blood Cancer
This strategy, which uses patients’ own immune cells, genetically engineered to target tumors, has shown significant success against multiple myeloma, a cancer of the plasma cells that is largely incurable.
TOPLESS Plants Provide Clues to Human Molecular Interactions
Scientists at Van Andel Research Institute have revealed an important molecular mechanism in plants that has significant similarities to certain signaling mechanisms in humans, which are closely linked to early embryonic development and to diseases such as cancer.
Toxin from Salmonid Fish has Potential to Treat Cancer
Researchers from the University of Freiburg decode molecular mechanism of fish pathogen.
Scientists Create CRISPR/Cas9 Knock-In Mutations in Human T Cells
In a project spearheaded by investigators at UC San Francisco, scientists have devised a new strategy to precisely modify human T cells using the genome-editing system known as CRISPR/Cas9.
Long-sought Discovery Fills in Missing Details of Cell 'Switchboard'
A biomedical breakthrough reveals never-before-seen details of the human body’s cellular switchboard that regulates sensory and hormonal responses.
Tracking Breast Cancer Before it Grows
A team of scientists led by University of Saskatchewan researcher Saroj Kumar is using cutting-edge Canadian Light Source techniques to screen and treat breast cancer at its earliest changes.
SELECTBIO

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,400+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,700+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FREE!